Breaks Categories: News

ThursdayAug 24, 2017 12:22 pm

NetworkNewsBreaks – Identiv, Inc. (NASDAQ: INVE) Expands Partnership with PSA Security Network with New Physical Security Solutions Distribution Deal

Identiv (NASDAQ: INVE) this morning said it has expanded its partnership with PSA Security Network (PSA) to distribute the company’s full suite of Hirsch physical access control system (PACS) and security management solutions. The distribution agreement includes Hirsch Velocity Software, Hirsch Mx Controllers, Hirsch ScramblePad Reader Family, uTrust TS Reader Family, and uTrust TS Cards. “This expanded partnership with PSA provides our end-user base with a network of highly qualified security systems integrators that can offer installation and support services in a consistent and professional manner to key markets across the country,” Identiv VP of marketing and business development John…

Continue Reading

ThursdayAug 24, 2017 9:16 am

NetworkNewsBreaks – PotNetwork Holdings, Inc. (POTN) Subsidiary Achieves 30% Month-Over-Month Revenue Growth in July

PotNetwork Holdings, Inc. (OTC: POTN) this morning announced that its wholly owned subsidiary, Diamond CBD, Inc., has delivered a considerable month-over-month increase in revenues, recording $1,459,137 for the month of July. This total exceeded the company’s June revenues by more than 30 percent. “We are very pleased with how the numbers have continued to gain over the summer,” Maria Gomez, regional vice president of sales for Diamond CBD, Inc., stated in the news release. “We are consistently setting new sales records month after month and are excited to be able to report this type of continuing growth. We have taken…

Continue Reading

WednesdayAug 23, 2017 1:55 pm

NetworkNewsBreaks – Tandem Diabetes Care, Inc. (NASDAQ: TNDM) Sets Launch of t:lock™ Connector for its Insulin Pump Cartridges and Infusion Sets

Tandem Diabetes Care (NASDAQ: TNDM) this morning said it is preparing to launch its t:lock™ connector for its insulin pump cartridges and infusion sets, with the gradual rollout set to begin September 5. Additionally, all infusion sets currently offered by Tandem will be made available with the new t:lock connector and the company expects to fully transition by the end of 2017. The t:lock versions of Tandem’s current infusion sets will be sold under the brand names AutoSoft™, VariSoft™ and TruSteel™. “This launch strengthens our overall insulin delivery systems, addressing one of our customers’ most frequent requests to make the…

Continue Reading

WednesdayAug 23, 2017 12:34 pm

NetworkNewsBreaks – Celldex Therapeutics, Inc. (NASDAQ: CLDX) Completes Patient Enrollment in METRIC Study

Celldex Therapeutics (NASDAQ: CLDX) this morning said that it has completed patient enrollment in its phase 2b METRIC study of glembatumumab vedotin (glemba) in patients with metastatic triple negative breast cancers that overexpress gpNMB. The antibody-drug conjugate, glemba, works by targeting and binding to the protein expressed by multiple tumor types, gpNMB. The company expects that topline primary endpoint data will be reported in the second quarter of 2018. "Patients with triple negative breast cancer have very limited treatment options. We believe glemba holds significant promise as a potential new targeted treatment for patients with this devastating disease and look…

Continue Reading

WednesdayAug 23, 2017 12:32 pm

NetworkNewsBreaks – Novavax, Inc.’s (NASDAQ: NVAX) Preclinical NanoFlu™ Study Published in Vaccine

Shares of Novavax (NASDAQ: NVAX) are up 4% following the company’s news that data from a preclinical study have been published in the journal, ‘Vaccine.’ The preclinical study of the company’s influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, NanoFlu™, suggests that NanoFlu has the potential to provide a stronger immune response than influenza vaccines currently available to older adults. “The data in this publication further validate our nanoparticle vaccine platform and provide a strong rationale for advancing NanoFlu into a Phase 1/2 clinical trial. Our goal is to deliver a superior, differentiated vaccine to the greater than $3 billion…

Continue Reading

WednesdayAug 23, 2017 9:17 am

NetworkNewsBreaks – PotNetwork Holdings, Inc. (POTN) Adds Dr. David Feldbaum to Newly Formed Advisory Board

PotNetwork Holdings, Inc. (OTC: POTN) this morning announced the addition of Dr. David M. Feldbaum MD, FACS to its board of advisors. Feldbaum is certified in vascular surgery by the American Board of Surgery, having completed a surgical residency at Montefiore Medical Center/Albert Einstein College of Medicine in New York City. “We are very pleased to have Dr. Feldbaum join our growing team of advisors,” Maria Gomez, regional vice president of sales for PotNetwork subsidiary Diamond CBD, stated in the news release. “We expect that his experience and wisdom will strengthen the Company’s position in the industry as we target…

Continue Reading

TuesdayAug 22, 2017 12:06 pm

NetworkNewsBreaks – Inpixon (NASDAQ: INPX) Enters New Partnership with GTRI to Boost Physical Cybersecurity Line; Shares Weighted by Q2 Results

Inpixon (NASDAQ: INPX) this morning said it has entered into a partnership with GTRI, an IT consulting and services company, to render comprehensive three-dimensional physical cybersecurity solutions, including Inpixon Indoor Positioning Analytics (IPA) Security Dome. Per the agreement, GTRI will leverage the company’s technology to enable government organizations and enterprises to identify any potential exposures while preserving security and compliance standards. Shares of Inpixon are down 14% mid-day, likely moving on the company’s second-quarter financial performance, reported yesterday. Revenues increased $1.8 million to $15.1 million, compared to the second quarter of last year; Inpixon’s non-GAAP net loss widened to ($1.89)…

Continue Reading

TuesdayAug 22, 2017 9:42 am

NetworkNewsBreaks – HighCom Global Security, Inc. (HCGS) Provides Update on Key Corporate Milestones

Leading security solutions provider HighCom Global Security, Inc. (OTC: HCGS) this morning offered an update on key milestones the company has achieved in its product technology this year. These include the February launch of four new hard armor models through its HighCom Armor Solutions, Inc. division and the July NIJ approval of two additional armor models, including a Level IIIa elite, lightweight, high-performance soft armor panel and a Level III++, multi-curve, hard armor ballistic plate. “The addition of these new products increases HighCom Armor's ability to equip our customers with high quality, in demand armor that has been the cornerstone…

Continue Reading

TuesdayAug 22, 2017 9:18 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Enters Letter of Intent to Acquire Dr. FeelGood

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that it has signed a letter of intent to acquire Dr. FeelGood, a profitable Phoenix-based medical marijuana company with plans to develop a proprietary delivery and ordering technology. Per the terms of the agreement, SinglePoint will acquire 51 percent of Dr. FeelGood through a combination of cash and stock, adding an additional revenue stream to SinglePoint while solidifying its acquisition-based revenue strategy. “This acquisition is right in our wheel house,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “I previously took a distribution company public on the NASDAQ…

Continue Reading

MondayAug 21, 2017 4:09 pm

NetworkNewsBreaks – Cardiome Pharma Corp. (NASDAQ: CRME) Shares Sink on Disappointing Regulatory Feedback

Shares of Cardiome Pharma Corp. (NASDAQ: CRME) are down 33% near market close, though pulling from a new 52-week low reached earlier in the day’s trading session. Cardiome this morning said the U.S. FDA has advised that the company’s proposed data package would not would not be sufficient to support a resubmission of the BRINAVESS New Drug Application (NDA). BRINAVESS is Cardiome’s antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF). “In our most recent communication with the FDA, we proposed resubmission of the NDA based upon the original file and six years of accumulated safety data…

Continue Reading